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Natural killer (NK) cells are cytotoxic lymphocytes
and play a vital role in controlling viral infections
and cancer. In contrast to B and T lymphopoiesis
where cellular and regulatory pathways have been
extensively characterized, the cellular stages of early
human NK cell commitment remain poorly under-
stood. Here we demonstrate that a LinCD34+
CD38+CD123CD45RA+CD7+CD10+CD127 popula-
tion represents a NK lineage-restricted progenitor
(NKP) in fetal development, umbilical cord blood,
and adult tissues. The newly identified NKP has
robust NK cell potential both in vitro and in vivo, gen-
erates functionally cytotoxic NK cells, and lacks the
ability to produce T cells, B cells, myeloid cells, and
innate lymphoid-like cells (ILCs). Our findings identify
an early step to human NK cell commitment and
provide new insights into the human hematopoietic
hierarchy.
INTRODUCTION
Developmental pathways from hematopoietic stem cells (HSCs)
to mature functional blood cells involve multiple stages where
progenitor cells, generated in the process, become increasingly
restricted in their lineage choices, ultimately developing into fully
committed unilineage cells (Orkin and Zon, 2008). In contrast to
the mouse, the human hematopoietic hierarchy is less well char-
acterized, and the coordination between lymphoid and myeloid
programs is still under scrutiny (Laurenti et al., 2013). Despite
the fact that several lymphoid-committed or primed progenitors
have been defined downstream of the LinCD34+CD38CD90+
CD45RACD49f+ HSCs in human bone marrow (BM) and umbil-
ical cord blood (CB) (Doulatov et al., 2010; Galy et al., 1995; Hoe-
beke et al., 2007), the existence and identity of a human common394 Immunity 43, 394–407, August 18, 2015 ª2015 Elsevier Inc.lymphoid progenitor (CLP) is currently less clear (Doulatov et al.,
2010; Hoebeke et al., 2007). Moreover, although the early human
B and T cell developmental stages have been characterized
(Doulatov et al., 2010; Haddad et al., 2004; Hao et al., 2001; Hoe-
beke et al., 2007), the cellular and regulatory pathways of natural
killer (NK) cell development are less understood.
NK cells are classically defined as CD3CD56+CD16+ cells
in human. Several recent studies have identified newpopulations
of innate-like lymphocytes (ILCs) and placed NK cells in group 1
of the expanding family of ILCs (Diefenbach et al., 2014; Hazen-
berg and Spits, 2014; Narni-Mancinelli et al., 2011; Walzer et al.,
2007).
NK cells are found in the peripheral blood, lymph nodes,
spleen, liver, peritoneal cavity, placenta, and uterine mucosa
(Yu et al., 2013) and are important for controlling viral infections
and cancer. NK cells can kill target cells that lack expression of
major histocompatibility complex (MHC) class Imolecules or that
express ligands for activating receptors, e.g., NKG2D, two prop-
erties commonly associated with transformed cells (Raulet and
Guerra, 2009). Furthermore, by producing cytokines (such as
tumor necrosis factor alpha [TNF-a] and interferon gamma
[IFN-g]), NK cells can regulate subsequent adaptive immune re-
sponses (Colonna et al., 2011).
In patients with acute myeloid leukemia, transplanted donor
NK cells expressing mismatched inhibitory receptors provided
graft versus leukemia effect in the absence of graft versus
host disease (Ruggeri et al., 2002). These and many other find-
ings are the basis of a large number of ongoing studies and clin-
ical trials for NK cell immunotherapy against cancer (Miller,
2013).
The current prevailing model suggests that adult BM is the pri-
mary site of NK cell development (Di Santo, 2006), although early
lymphoid progenitors with NK lineage potential have been also
identified in human tonsil (Freud et al., 2005), thymus (McClory
et al., 2012; Res et al., 1996), and liver (Moroso et al., 2011), sug-
gesting that some subsets of human NK cells develop extra
medullary. Maturation of human NK cells is characterized by
the loss of CD34 and C-KIT (CD117) expression (Freud et al.,
2006), followed by sequential upregulation of CD94, CD16, and
killer cell Ig-like receptors (KIR) (Freud andCaligiuri, 2006), where
the expression of the latter three receptors distinguishes NK
cells from other members of ILC family. Two functionally distinct
mature human NK cell populations exist in the peripheral blood:
the CD56dimCD16+ cytotoxic NK cells and the CD56brightCD16
NK cells that are mainly producing cytokines (Cooper et al.,
2009). The origin of these two NK cell subsets, their develop-
mental relationship, and their regulatory cues are not fully un-
derstood (Cooper et al., 2009; Di Santo, 2006). In addition, the
identity of human progenitors uniquely restricted to the NK line-
age (NKPs) remains unknown (Doulatov et al., 2010, 2012).
Using advanced multicolor flow cytometry with a new combi-
nation of markers important for human lymphoid commitment
(Haddad et al., 2004; Hao et al., 2001; Kohn et al., 2012), we iden-
tified a LinCD34+CD38+CD123CD45RA+CD7+CD10+CD127
NK cell-restricted progenitor (NKP), downstream of LMPP
(LinCD34+CD38CD90CD45RA+) (Roy et al., 2012) and
CLP-like cells (LinCD34+CD38+CD123CD45RA+CD7+CD10+
CD127+), in human bone marrow, umbilical cord blood, tonsils,
and fetal tissues. NKPs generated fully mature and functional
NK cells both in vitro and in vivo and lacked the potential to pro-
duce T cells, B cells, ILCs, or myeloid cells at the single-cell level
in vitro and after transplantation into newborn NOD/SCIDgcnull
mice. Our identification of the earliest steps of human NK cell
commitment, conserved throughout ontogeny, provides new
insights into human hematopoiesis with implications for the
development of NK cell-based therapies.
RESULTS
Lin–CD34+CD38+CD123–CD45RA+CD7+CD10+CD127–
Are Candidate NK Cell Progenitors
Given published reports linking the expression of early lymphoid
markers (CD45RA, CD10, CD7) (Doulatov et al., 2010; Galy et al.,
1995; Haddad et al., 2004; Hao et al., 2001; Hoebeke et al., 2007;
Kohn et al., 2012) and IL-7 receptor (IL-7R, CD127) (Blom and
Spits, 2006) to lymphoid development, we applied these
markers to identify NKP candidates in human hematopoiesis.
When 500, 10, or 1 LinCD34+CD38+CD123CD45RA+CD7+
CD10+CD127 cells purified from CB (Figure 1A) or BM (Fig-
ure 1B) were co-cultured on OP9 or OP9DL1 stroma, all the wells
contained viable CD16+ and CD16 CD19CD3CD56+NKp46+
NK cells, but no other blood cell lineages (Figures 1C–1E, S1A–
S1G, and S2A–S2C). Further phenotypic analysis demonstrated
that NK cells generated in vitro from LinCD34+CD38+
CD123CD45RA+CD7+CD10+CD127 candidate NKPs ex-
pressed multiple NK cell receptors, including NKp46, CD94,
KIR, CD57, CD27, CD161, CD244, and NKG2D (Figure S1E).
Purified multipotent CB or BM LinCD34+ cells were used
as positive controls, and in addition to NK cells, they also pro-
duced CD19+ B cells, CD5+CD4+/CD8+/CD3+/ T cells, and
CD33+CD14+ myeloid cells (Figures 1C–1E, S1A–S1E, and
S3A), andmultiple lineage output was observed at the single-cell
level. Similar results were observed for purified LinCD34+
CD38+CD123CD45RA+CD7+CD10CD127 cells (Figure S3B),
whereas only lymphoid lineages (T, B, ILCs, NK cells) were
generated from 10 or 1 purified LinCD34+CD38+CD123
CD45RA+CD7+CD10+CD127+ cells (CLP-like cells) (Figures 1C
and S3A).The LinCD34+ progenitors in addition to cytotoxic CD56+
CD16+NKp46+ NK cells (Figures 1C, S1A–S1G, S2A–S2C, and
S3A) also generated IL-7R-expressing innate lymphoid-like
cells (IL-7R+ ILCs) that could be subdivided into ILC1
(C-KITNKp44IL-7R+), ILC2 (C-KIT+/IL-7R+CRTH2+), and
ILC3 (C-KIT+NKp44+/IL-7R+) (Figures 1C, S1G, and S2A–S2C;
Hazenberg and Spits, 2014). IL-7R+ ILCs generated from
LinCD34+ expressed RORgt and GATA-3, whereas the NKP-
derived progeny expressed EOMES and T-BET, but not RORgt
or GATA-3 (Figures S2A–S2C). IL-7R+ ILCs were also clearly
present in cultures generated from ten LMPPs and ten CLP-
like cells (Figures 1C and S3A). In contrast, the progeny pro-
duced from the candidate NKP had a uniform IL-7RCD56+
CD94+CD16+C-KIT phenotype compatible with conventional
cytotoxic NK cells (Figures 1C, S1E, and S1G; Hazenberg and
Spits, 2014), demonstrating that the NKP candidate had no abil-
ity to generate IL-7R+ ILCs in vitro.
Next, we evaluated the generation of macrophages and gran-
ulocytes from NKPs and LinCD34+ cells using a single-cell
myeloid culture assay (Terasaki culture). Whereas approxi-
mately 70% of single LinCD34+ cells producedmedium or large
clones, very few (1%–2%) single NKPs generated small
clones (Figures S1B–S1D). The clones generated from Lin
CD34+ cells contained macrophages, granulocytes, and
erythroid cells (Figure S1C), whereas the clones generated
from NKPs contained cells with lymphoid morphology (Fig-
ure S1D). These findings established, at the single-cell level,
that the LinCD34+CD38+CD123CD45RA+CD7+CD10+CD127
cell population has a robust NK lineage potential in vitro and
lacks the ability to generate T, B, non-NK cell ILCs, and myeloid
cells.
NKP Lacks Expression of Mature NK Cell Markers and Is
Present in Fetal Tissues and Adult Tonsil
To further characterize the NKP candidate population, we
investigated the expression of additional cell surface markers
known to be important for the lymphoid commitment and NK
cell development. CD62L and CD244 molecules were highly
expressed on the NKP candidate both in CB and BM (Figures
2A and 2B). In contrast, cell surface receptors expressed by
mature NK cells, such as NKp46 and NKG2D, were not detect-
able on NKPs. Approximately 70% of CLP-like cells (Figure 2A)
and 50% of NKPs expressed C-KIT and FLT3 receptors, and
only a few NKPs were positive for CSF-1R, the third member
of the class III cytokine tyrosine kinase family. NKPs did
not express detectable levels of the IL-2/IL-15 receptor b
(CD122), but 30% to 40% expressed the common g chain,
CD132 (Figures 2A and 2B). Finally, NKPs did not express
detectable levels of CD27 (TNF- receptor) or CD161 (Figures
2A and 2B).
The LinCD34+CD38+CD123CD45RA+CD7+CD10+CD127
NK cell-restricted progenitor was also detected in human fetal
liver (FL) at gestational weeks 6, 10, 12, and 16, and in fetal
bone marrow (FBM) at gestational weeks 12 and 16 (Figure 2C).
Finally, NKPs were also present in adult tonsils (Figure 2D) and,
after in vitro co-culture on OP9 stroma, these tonsil NKPs gave
rise only to CD56+NKp46+CD16+NKG2D+CRTH2 NK cells,
compatible with the phenotype of cells generated from CB and
BM NKPs (Figure S3C).Immunity 43, 394–407, August 18, 2015 ª2015 Elsevier Inc. 395
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NK Cells Generated In Vitro from NKPs Are Functional
To determine whether in vitro produced NK cells were function-
ally competent, we performed a CD107a degranulation assay
(Bryceson et al., 2005). NK cells generated from NKPs cultured
with OP9 stromal cells upregulated CD107a after activation
with PMA/ionomycin, anti-CD16 antibody, or the K562 leukemic
cell line (Figures 3A and 3B). Similar results were obtained with
NK cells generated from NKPs cultured with OP9-DL1 stromal
cells (data not shown). In addition, the supernatants of the acti-
vated NK cells generated from NKPs contained higher amounts
of IFN-g and TNF-a, compared to unstimulated controls (Figures
3C and 3D and data not shown). Finally, NK cells generated from
NKPs did not produce detectable amounts of IL-13, IL-5, and IL-
22 cytokines (Hazenberg and Spits, 2014), in contrast to IL-7R+
ILCs generated from LinCD34+ progenitors (Figures 3E and 3F).
Taken together, these data demonstrated that NK cells gener-
ated in vitro from the LinCD34+CD38+CD123CD45RA+CD7+
CD10+CD127 NKPs are functionally mature.
The NKP Candidate Generates Only NK Cells after
Transplantation into Newborn Immune-Deficient Mice
Next, we examined the ability of the NKP candidate to engraft
and generate hematopoietic cells after transplantation into
sublethally irradiated newborn NOD/SCIDgcnull mice (Ito et al.,
2002). At 11 weeks after transplantation, 15 out of 17 mice trans-
planted with 600 LinCD34+ multipotent cells had detectable
numbers of human cells in the peripheral blood, bone marrow,
and spleen, and 9 out of 17 transplanted mice had detectable
levels of human cells in the thymus (Figures 4A–4C and S4A–
S4C). Furthermore, mice had amultilineage reconstitution where
human B (CD56CD3CD19+), T (CD19CD56CD5+CD4+/
CD8+/CD3+/), NK (CD19CD3CD56+NKp46+CD16+/), and
myeloid (CD14+CD33+) cells were present in all analyzed tis-
sues (Figures 4A–4C and S4A–S4C). In contrast, mice trans-
planted with 600 LinCD34+CD38+CD123CD45RA+CD7+
CD10+CD127 NKPs had clearly detectable human CD19
CD3CD56+NKp46+CD16+/ NK cells in the peripheral blood,
bone marrow, spleen, and thymus, and no other lineages were
detected (Figures 4A–4C and S4A–S4C). Essentially all NK cells
produced in NOD/SCIDgcnull mice after transplantation withFigure 1. Identification and Purification of the Human NK Cell Progeni
(A and B) Human CD34+ cells (A) from umbilical cord blood (CB) and (B) bone m
CD10, and CD127 markers and the NKP candidate (LinCD34+CD38+CD123
percentages in indicated gates or boxes and arrows show the gating strategy.
(A) Top and bottom panels show the sort gates and the reanalysis after sort of the
Data are representative of 13 different analyses of CB batches (2–6 donors for e
(B) Panels show the sorting gates of NKPs from BM. Data are representative of 8
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LinCD34+, LinCD34+CD38CD90CD45RA+ LMPPs, LinCD34+CD38+CD
CD123CD45RA+CD7+CD10+CD127 NKPs after 4 weeks of culture on OP9 (B c
(T cells). Wells were considered positive when at least 30 viable human cells we
20 cells with the required phenotype were detected. Data represent mean (SD
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stroma for 4 weeks and (E) OP9DL1 stroma for 5 weeks. Numbers represent freq
also Figures S1, S2, and S3.NKPs were CD56+NKp46+ (Figures 4A–4C and S4A–S4C). In
contrast to the cohort transplanted with LinCD34+ population
(Figure 4D), CD127+ RORgt+ or CRTH2+ cells were undetectable
in mice transplanted with NKPs, demonstrating that the NKP
candidate did not have the ability to generate IL-7R-expressing
ILCs in vivo (Figure 4D).
Collectively these results demonstrated that NKPs engraft in
newborn NOD/SCIDgcnull mice and lead to exclusive NK cell
reconstitution after transplantation.
NK Cells Generated In Vivo from NKP Candidate Are
Cytotoxic and Secrete Cytokines
Next, we investigated whether in vivo generated NK cells were
mature and cytotoxic. Human NK cells purified from spleens
of reconstituted NOD/SCIDgcnull mice after activation with
PMA/ionomycin or with K562 tumor cells had significantly
higher expression of CD107a compared to unstimulated control,
regardless of whether they were isolated frommice transplanted
with NKPs or LinCD34+ cells (Figure 5A). When human NK cells
produced in NOD/SCIDgcnull mice transplanted with NKPs were
divided into CD16+ and CD16 fractions, the CD16 cells
showed significantly lower cytotoxic activity compared to the
CD16+ fraction (Figure 5B). Furthermore, in vivo generated NK
cells produced detectable amounts of IFN-g and TNF-a (Fig-
ure 5C) and expressed multiple NK cell receptors, including
NKp46, KIR, CD94, CD57, CD27, NKG2D, CD161, and CD244
(Figure 5D). In summary, our data established that NK cells
derived from NKPs after transplantation into NOD/SCIDgcnull
mice were mature and were functionally and phenotypically
similar to mature NK cells isolated from peripheral blood.
NK Cell Lineage-Associated Genes Are Specifically
Upregulated in NKPs
To define the transcriptional signature of the NKPs, we
performed a genome-wide microarray gene expression anal-
ysis on purified NKPs (LinCD34+CD38+CD123CD45RA+
CD7+CD10+CD127) and compared them to upstream multi-
potent progenitors LMPPs (Roy et al., 2012) (LinCD34+
CD38CD90CD45RA+) and mature NK cells (CD56+NKp46+
CD3CD19) purified from CB. The differentially expressedtor Candidate in Bone Marrow and Umbilical Cord Blood
arrow (BM) were analyzed for the expression of CD38, CD123, CD45RA, CD7,
CD45RA+CD7+CD10+CD127) was sorted as indicated. Numbers represent
LinCD34+CD38+CD123CD45RA+CD7+CD10+CD127 population from CB.
ach batch).
different BM donors.
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C-KIThi/lo), and myeloid cells (CD14+CD33+) generated from purified CB
123CD45RA+CD7+CD10+CD127+ CLP-like cells, and LinCD34+CD38+
ells, NK cells, ILCs, and myeloid cells) and after 5 weeks of culture on OP9DL1
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probes (1,530) were clustered into 6 different groups via
k-means, where a NKP-specific signature was identified (Fig-
ure 6A). Some key lymphoid-specific genes such as EBF-1,
RAG-1, and PAX5 were expressed at higher levels in NKPs as
compared to LMPPs (Figure 6B). To determine whether this
increase was specific to NKPs, we compared the expression
of these genes to the CLP-like cells (LinCD34+CD38+
CD123CD45RA+CD7+CD10+CD127+) that, in the hematopoiet-
ic hierarchy, are placed upstream of NKPs and downstream to
LMPPs. No significant differences were detected for EBF-1,
RAG-1, and PAX5 expression between the CLP-like cells and
NKP populations (Figure 6B), which suggested that the expres-
sion of lymphoid genes was maintained but not upregulated
in NKPs. To confirm these findings, we performed an expres-
sion analysis on 25 purified NKPs, CLP-like cells, LMPPs,
mature NK cells, myeloid (LinCD34+CD38+CD123+), and
B cell (LinCD34+CD38+CD123CD45RA+CD19+) progenitors
using quantitative gene expression analysis. The expression
of erythroid-specific gene (GATA1), myeloid genes (GCSF2R,
PU.1), and B-cell-specific genes (CD79A, PAX5, EBF-1) was
lower in NKPs compared to upstream CD34+ progenitors,
LMPPs, CLP-like cells, as well as B cell and myeloid progenitors
(Figure 6C and data not shown). Consistent with their robust
NK cell potential, the NKPs expressed higher levels of several
genes important for regulation of early lymphoid and NK cell
development (GATA3, EOMES, TBX21, CD122, CD247) and
several NK-cell-related genes (NCAM1, NCR1, KLRB1,
KIR2DL2,PERFORIN, andGRANZYMEB) (Figure 6C).Moreover,
ILC-associated genes (RORA, RORC, IL-17, IL-22, IL-5, and IL-
13) were not upregulated in NKP compared to LMPP or CLP-
like cells (Figure S5A). Similar results were also obtained with
the same cell populations isolated from human BM (Figure S5B).
These results demonstrate that the identified NKP exhibits
strong NK lineage priming, whereas expression of genes associ-
ated with several other blood lineages is downregulated.
Human NKP Is Downstream of LMPP and CLP-like Cells
in the Hematopoietic Hierarchy
To place the newly identified NKP within the human hemato-
poietic hierarchy, we analyzed the progenies generated from
LinCD34+ multipotent progenitors, purified LMPPs, CLP-like
cells, and NKPs in vitro and in vivo.
First, we analyzed the phenotype of the progeny of purified
LinCD34+CD38CD90CD45RA+ LMPPs, LinCD34+CD38+
CD123CD45RA+CD7+CD10+CD127+ CLP-like cells, and Lin
CD34+CD38+CD123CD45RA+CD7+CD10+CD127 NKPs (Fig-
ure 7A) after co-culture on OP9 stroma at different time points.
After 2 days of culture, LMPPs gave rise predominantly to
CLP-like cells, whereas very few NKPs were detected at this
time (data not shown). After 4 days, there were no detectableFigure 2. The NKP Lacks the Expression of Mature NK Cell Markers a
(A and B) Human CD34+ cells from BM (A) and from CB (B) were analyzed for th
CD27, FLT3, C-KIT, CSF1R, CD62L, NKp46, NKG2D, CD244, and CD161. Data
(C) Representative FACS profile of liver (FL) from 6-, 10-, and 12-week-old fetuses
and two different BM were analyzed for each time point.
(D) Representative FACS profile of adult tonsil, results are representative of thre
represents frequencies in indicated gates or boxes and arrows show the gating
See also Figure S3.LMPPs left in the culture, although the generated progeny
contained CLP-like cells, NKPs, and lineage-positive cells (Fig-
ure 7B). Purified CLP-like cells could be maintained in culture
for 4 days while producing NKPs as well as lineage-positive cells
(Figure 7B). In contrast, NKPs did not give rise to CD127+ cells,
and only lineage-positive cells were detected in the wells (Fig-
ure 7B). Although NKPs did not express detectable levels of
CD122 ex vivo, more than 70%of the NKPswere CD122 positive
after 4 days in culture, and all NKPs generated from CLP-like
cells and LMPPs showed high cell surface expression of
CD122 at day 6 (Figure 7B).
Next, we investigated the CD34+ hematopoietic progenitor
compartment in the BM of NOD/SCIDgcnull mice transplanted
with human multipotent CB LinCD34+ cells, NKPs, and LMPPs.
At 3 weeks after transplantation with LinCD34+ cells (Fig-
ure S6A), the BM of reconstituted mice predominantly contained
a population of myeloid progenitors expressing IL-3 receptor
(CD123+) and a CD45RA+CD7+CD127+ population that started
to co-express CD10; however, the NKP population was not
detectable at this time. Later, 4 weeks after transplantation (Fig-
ure S6A), the frequency of CD123+ cells was reduced, and the
lymphoid progenitors were increased: NKPswere clearly detect-
able in the BM, together with the CLP-like cells and other early
hematopoietic progenitors expressing CD127, CD10, or CD7
lymphoid markers (Figure S6A). Importantly, NKPs generated
in NOD/SCIDgcnull mice transplanted with human LinCD34+
cells produced only CD56+NKp46+CD16+ NK cells in culture
on OP9 stroma (Figure S6B). At 4 weeks after transplantation
of NKPs into NOD/SCIDgcnull mice, NKPs were detected in the
BM of 3 out of 14 mice (Figure S6C), and at this time, mature
CD56+NKp46+CD16 NK cells were present mainly in the BM
(data not shown).
Finally, the analysis of BM from NOD/SCIDgcnull mice
transplanted with purified LMPPs supports that CLP-like
cells were generated first followed by the generation of NKP
(Figure S6D).
Collectively these data suggest that the candidate NKP repre-
sents a progenitor downstream of LMPP and CLP-like cells.
DISCUSSION
With the identification of a restricted NK cell progenitor in adult
BM, tonsil, umbilical CB, and fetal tissues, we here report several
findings that contribute to a greater understanding of human
lymphoid and NK cell development.
Despite several recent advances in knowledge of NK cell
biology, including their functional regulation and differentiation,
the developmental stages from CD34+ precursors to mature
NK cells remain relatively less known. In particular, the identity
of a NK-cell-restricted progenitor has remained elusive, despitend Is Present in Fetal Tissues and Adult Tonsils
e expression of CD38, CD123, CD45RA, CD7, CD10, CD127, CD132, CD122,
are representative of four independent experiments for each tissue.
and bone marrow (FBM) of 12- and 16-week-old fetuses. Three different livers
e independent experiments (three different donors were analyzed). Numbers
strategy.
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Figure 3. Human NK Cells Generated
In Vitro from NKP Are Functionally Mature
(A) Representative FACS profiles of CD107a
expression on NK cells generated in vitro from CB
NKPs, either non-stimulated, or after stimulation
with PMA/ionomycin, anti-CD16 antibody, or K562
tumor target cells using 1:1 and 1:10 effector to
target (E:T) ratio. Data are representative of five
independent experiments.
(B) Percentage of CD107a+ NK cells generated
in vitro from LinCD34+CD38+CD123CD45RA+
CD7+CD10+CD127 NKPs purified from CB (left)
and BM (right) cultured on OP9 stroma for
4 weeks. Data represent mean values and SD from
five independent experiments for NK cells gener-
ated from CB NKP (ten wells seeded with ten cells
were pooled for each experiment, on each stroma
OP9 and OP9-DL1; data not shown) and four in-
dependent experiments for BM NKP-generated
NK cells (ten wells seeded with ten cells were
pooled for each experiment, on each stroma
OP9 and OP9-DL1; data not shown). Mann-
Whitney test was used for statistical analysis.
**p value < 0.005.
(C and D) Levels of IFN-g (C) and of TNF-a (D)
produced by NK cells generated in vitro from
CB (left) and BM (right) LinCD34+CD38+
CD123CD45RA+CD7+CD10+CD127 NKPs
cultured onOP9 stroma, non-stimulated (CTR) and
after activation with PMA, anti-CD16 antibody, or
K562 tumor target cells using 1:1 and 1:10 effector
to target (E:T) ratio. Data represent mean values
and SD from four independent experiments for
CB- and BM-generated NK cells from NKPs.
Similar results were obtained for NK cells gener-
ated on OP9DL1 (data not shown). Supernatants
were generated from cells used in (A) and (B).
Mann-Whitney test was used for statistical anal-
ysis. *p value < 0.05.
(E) Representative profiles showing secretion of
IL-5, IL-13, IL-22, and IFN-g by IL-7R+ ILCs
generated from LinCD34+ cells or progeny
derived from NKPs after 3-week culture on OP9
stroma. Data are representative of two indepen-
dent experiments with three wells analyzed for
each cytokine.
(F) Representative profiles showing secretion of
IL-5 and IL-13 by CD127+ ILCs positive for IL-13
and IL-22 or for IL-5 and IL-22, respectively,
generated from LinCD34+ cells after 3-week
culture on OP9 stroma. Data are representative
of two independent experiments with three wells
analyzed.several reports on hematopoietic precursor cells with the capac-
ity to generate NK cells.
Previous studies have characterized the early lymphoid
committed progenitors in human BM and CB as being
LinCD34+CD38+CD10+ (Galy et al., 1995) and LinCD34+
CD38CD7+ (Hoebeke et al., 2007) cells, respectively, with
the ability to generate T, B, and NK cells, but not myeloid
cells. More recently a study has described a LinCD34+400 Immunity 43, 394–407, August 18, 2015 ª2015 Elsevier Inc.CD38CD45RA+CD10+CD7 immature lymphoid progenitor in
human BM and CB, called MLP, that gives rise to T, B, and NK
cells, but also maintains the ability to produce dendritic cells,
monocytes, and macrophages (Doulatov et al., 2010). Here, we
demonstrate that the LinCD34+CD38+CD123CD45RA+CD7+
CD10+CD127+ cells represent a human CLP-like cell, with a
lineage potential restricted to the lymphoid cells and a strong
lymphoid gene priming.
More importantly, we demonstrate that a human NK-cell-
restricted progenitor can be identified in adult bone marrow,
tonsil, cord blood, and fetal tissues as a distinct population of
LinCD34+CD38+CD123CD45RA+CD7+CD10+CD127 cells.
This progenitor has a robust NK cell lineage potential and lacks
the ability to generate other blood lineages at the single-cell level
in vitro. The phenotype of this newly identified NKP is consistent
with previous phenotypes of early lymphoid progenitors and
represents a novel intermediate stage within the human hemato-
poietic hierarchy.
Recently, it has become evident that the family of ILCs is very
heterogeneous, and in addition to cytotoxic NK cells, contains
CD127+ ILC1, ILC2, and ILC3 cells (Diefenbach et al., 2014; Ha-
zenbergandSpits, 2014). Previously, aprogenitorwithNKcell po-
tential was identified in human lymph nodes (Freud et al., 2005),
which originates from BM CD34+ progenitor cells that express
CD45RA, CD10, CD7, C-KIT, and L-selectin (CD62L) (Freud
et al., 2005, 2006).However, this population in addition toNKcells
can generate T cells (Freud et al., 2006) and it remains to be deter-
mined whether they can also produce CD127+ ILCs. Indeed, an
ILC3-restrictedCD34+CD45RA+CD161+CD117+precursor (Mon-
taldo et al., 2014), partially overlapping with the phenotype of
the precursor described by Freud et al. (2005), was very recently
identified in human tonsils. In contrast, the newly identified NKP
had no ability to produce IL-7R+RORgt+ or IL-7R+CRTH2+ ILCs
in vitro or in vivo, in agreement with a recently proposed model
for the development of ILC lineages where NKP represents a
separate branch downstream of the CLP, which generates only
cytotoxic NK cells (Diefenbach et al., 2014). Our data are compat-
ible and in agreement with this model, but most importantly pro-
vides the identity of a cytotoxic NK cell-restricted progenitor.
The LinCD34+CD38+CD123CD45RA+CD7+CD10+CD127
NKP identified here can also be detected in human tonsils, and
also probably overlaps partially with the population described
by Freud et al. (2005) based on the common co-expression of
CD7, CD10, CD62L, and C-KIT. Importantly, however, the NKP
identified here is clearly distinct from the recently identified
ILC3 precursor, because it did not express RORgt or CD161, uni-
formly expressed CD7, and did not give rise to non-NK cell ILCs
in vitro or in vivo.
The development of human NK cells in the fetus is not well
characterized and it has been shown that populations of human
T, B, and NK cells generated from fetal stem and progenitor cells
have different functional properties than those generated post-
natally in adult (Ivarsson et al., 2013; Mold et al., 2010; Punnonen
et al., 1992). Although NK cells can be detected in human fetal
liver already at gestational week 6 (Phillips et al., 1992), it is
not known when and where NK cell progenitors arise during
fetal development. Here we show that LinCD34+CD38+
CD123CD45RA+CD7+CD10+CD127 NKPs were present in
fetal liver between gestational weeks 6 and 16. In addition, we
also detected NKPs in fetal bone marrow at gestational weeks
12, 15, and 16, which represent a time when the bone marrow
becomes an active site for hematopoiesis.
Human NK cell maturation involves the sequential loss of
CD34 and C-KIT expression (Freud et al., 2006), followed by up-
regulation of CD56, CD94, CD16, and KIRs (Freud and Caligiuri,
2006). The NKP candidate progenitor did not express detectable
cell surface levels of proteins associated with mature NK cellsex vivo, whereas the NK cells generated in vitro and in vivo
proceeded through the expected phenotypic and functional
maturation stages.
Interleukin-15 (IL-15) has been identified as a key cytokine
important for in vitro and in vivo differentiation of mouse and hu-
man NK cells, and human CD34+ cells respond to IL-15 in vitro
(Cooper et al., 2002; Freud and Caligiuri, 2006; Freud et
al., 2006; Ranson et al., 2003). The cell surface expression of
the b subunit of the IL-15 receptor (CD122) on human lymphoid
progenitors is, however, undetectable by flow cytometry (Freud
and Caligiuri, 2006; Freud et al., 2006). In agreement with this,
NKPs did not express detectable levels of CD122 ex vivo, but
it was clearly detectable after 4 days in culture in the presence
of cytokines, demonstrating that IL-15 is important for NK cell
differentiation from NKPs.
A NOD/SCIDgcnull mouse xeno-transplantation model was
previously shown to support engraftment of human hematopoi-
etic progenitors and generation of T, B, myeloid, and CD56dim
cytotoxic NK cells (Brehm et al., 2010; Chan et al., 2007; Ito
et al., 2002).
In contrast to previous studies where the lineage potential of
identified lymph node NK progenitor was not investigated in vivo
(Freud et al., 2005, 2006), we show that 41%–53% of the mice
transplanted with 600 purified NKPs had clearly detectable
levels of human NK cell in the peripheral blood, spleen, and
bone marrow. Importantly, no other blood lineages were pro-
duced, supporting our assertion that NKPs represent a novel,
tightly restricted NK cell progenitor. Furthermore, human NK
cells generated from transplanted NKPs expressed typical
NK cell surface molecules and, according to the NK matura-
tion stages, were phenotypically and functionally defined as
CD56dimCD16+ cytotoxic NK cells and CD56brightCD16 cyto-
kine-producing NK cells (Chan et al., 2007; Cooper et al.,
2009). Moreover, NKPs showed a significant upregulation of
genes important for NK cell development (EOMES and TBX21),
as well as genes involved in cytotoxic killing (PERFORIN and
GRANZYME B), whereas the B cell and myeloid cell genes
were downregulated.
In agreement with the recent studies on human hematopoiesis
(Doulatov et al., 2010, 2012; Laurenti et al., 2013; Roy et al.,
2012), the expression of EBF-1 and other early lymphoid genes
was upregulated already in early lymphoid progenitors MLP
and LMPP. Interestingly, we found that EBF-1 expression re-
mained at comparable levels in CLP-like cells and NKPs, despite
the fact that NKPs had no ability to generate B cells. NKPs also
expressed high levels of CD62L on the cell surface, which coin-
cides with lymphoid priming (Kohn et al., 2012). Genes related to
NK cell effector functions, including NK-cell-mediated cytotox-
icity, secretory pathways, and CD16 (FcgRIIIa), were upregu-
lated in the NKP candidate, further supporting its NK lineage
restriction and function. In contrast, and consistent with the
finding that NKPs failed to generate CD16IL-7R+ ILCs, there
was no upregulation of non-NK ILC-associated genes, e.g.,
RORA, RORC, IL-17, IL-22, IL-5, and IL-13 (Figures 6 and S5A).
Previous studies reported a high expression of GATA3 and
identified GATA3 as an important regulator of mouse thymic
NK cells (Vosshenrich and Di Santo, 2013). We found that the
expression of GATA-3 was upregulated in NKPs compared to
other early lymphoid progenitors. This suggests that the newlyImmunity 43, 394–407, August 18, 2015 ª2015 Elsevier Inc. 401
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Figure 5. Human NK Cells Generated from NKP after Transplantation into Immune-Deficient Mice Are Functionally Mature
(A) Percentage of CD107a+ CD45+CD3CD56+NKp46+ human NK cells generated from 600 CB LinCD34+CD38+CD123CD45RA+CD7+CD10+CD127 NKPs
(black bars) or 600 LinCD34+ cells (gray bars) sorted from NOD/SCIDgcnull mice spleen at 11 weeks after transplantation. Data represent mean values and SD
from three independent experiments with six mice analyzed in total.
(B) Percentage of CD107a+ NK cells within CD16+ (black bars) and CD16 (gray bars) NK cell fractions generated in vivo from 600 CB LinCD34+CD38+
CD123CD45RA+CD7+CD10+CD127 NKPs and 600 LinCD34+ control cells, non-stimulated (CTR) and after activation with PMA or K562 tumor target cells
using 1:1 and 1:10 effector to target (E:T) ratio. Data represent mean values and SD from two independent experiments with three mice analyzed in total.
(C) Levels of TNF-a and IFN-g produced in vitro by human CD45+CD3CD56+ NK cells generated in vivo from 600 LinCD34+CD38+CD123CD45RA+CD7+
CD10+CD127 NKPs at 11 weeks after transplantation into NOD/SCIDgcnull mice, non-stimulated (CTR) and after activation with PMA and K562 target tumor
cells using 1:1 and 1:10 E:T ratio. Data represent mean (SD) values from three independent experiments with six mice analyzed in total.
(D) Representative FACS profile of CD56, CD16, NKp46, CD94, CD244, CD161, CD27, KIR receptors, and NKG2D expression on sorted NK cells generated after
transplantation of NKP into NOD/SCIDgcnull mice. Data are representative of two independent experiments with four mice analyzed in total.identified NKP could also represent a progenitor for thymic NK
cells. In support of that, human NK cells were present in the
thymus of NOD/SCIDgcnull mice reconstituted after transplanta-
tion with human NKPs.
To investigate the developmental relationship between LMPP,
CLP, and NKP, we performed in vitro and in vivo studies and es-
tablished that LMPP can give rise to both CLP-like and NKP
cells, whereas CLP-like cells can generate only NK progenitors,
and NKPs cannot produce CLP-like cells. The placing of NKPs in
the hierarchy downstream of CLP and LMPPwas also supported
by C-KIT and FLT3 expression, which were high in LMPP,
decreased in CLP-like cells, and more reduced in NKPs, both
at the protein and mRNA level.
The proposed model of human hematopoietic hierarchy sug-
gests that HSCs differentiate into multilymphoid progenitorsFigure 4. The Human NKP Candidate Generates NK Cells but No Othe
(A) Proportion of human CD45+ cells in PB, BM, spleen, and thymus in recipient
3 independent experiments with 17 recipient mice transplanted with NKPs (circle
(B) Proportion of human NK (CD19CD3CD56+NKp46+CD16+/), B (CD56
(CD14+CD33+) cells within human CD45+ cells in different tissues of engrafted
experiments with 17 recipient mice transplanted with NKPs (black bars) and 17 m
potential detected.
(C) Representative FACS profiles of spleen from NOD/SCIDgcnull mice transpla
(top), 600 LinCD34+ cells (middle), or non-transplanted control (bottom), 11 we
(D) Representative FACS profiles of BM from NOD/SCIDgcnull mice transplan
CD7+CD10+CD127 NKPs (bottom) showing the generation of IL-7R+ ILCs (CD1
See also Figure S4.that give rise to the bi-potent B-NK cell precursors in the bone
marrow (Doulatov et al., 2010). Recent studies on hematopoiesis
in rhesus macaque by Wu et al. (2014) have challenged the
current hierarchy and suggested that NK cells originate from a
distinct progenitor with no clonal overlap with B, T, and myeloid
cell lineages (Wu et al., 2014). Our functional in vitro and in vivo
studies and the analysis of expression patterns of lineage-spe-
cific genes in NKPs, CLP-like cells, and LMPPs support that
NKPs are placed in the hematopoietic hierarchy downstream of
CLPs and LMPPs, with no ability to generate T, B, and myeloid
cells. Supporting this model, the previous work by Doulatov
et al. (2010, 2012) have demonstrated that generation of mature
NK cells from hematopoietic stem and progenitor cells occurs
through the intermediate stages including lympho-myeloid and
B-NK cell progenitors. The conclusions from the studies by Wur Lineages after Transplantation into Immune-Deficient Mice
mice transplanted with human cells. Data represent mean values and SD from
s) and 17 mice transplanted with LinCD34+ cells (squares).
CD3CD19+), T (CD19CD56CD5+CD4+/CD8+/CD3+/), and myeloid
mice. Data represent mean (SD) values of hCD45+ mice from 3 independent
ice transplanted with LinCD34+ cells (gray bars). Hatch sign (#) indicates no
nted with 600 LinCD34+CD38+CD123CD45RA+CD7+CD10+CD127 NKPs
eks after transplantation.
ted with 600 LinCD34+ cells (top), 600 LinCD34+CD38+CD123CD45RA+
27+CD56+/NKp44+/C-Kithi/lo), 11 weeks after transplantation.
Immunity 43, 394–407, August 18, 2015 ª2015 Elsevier Inc. 403
A B
C
G
AP
DH
G
AP
DH
G
AP
DH
Figure 6. The NKP Candidate Has a Distinct Genetic Signature from LMPP, CLP, and Mature NK Cells
(A) K-means clusters of differentially expressed genes between LMPP, NKP candidates, and mature NK cell populations.
(B) Gene expression of selected lymphoid genes in LMPP (LinCD34+CD38CD90CD45RA+), CLP-like (LinCD34+CD38+CD123CD45RA+CD7+CD10+
CD127+), NKP (LinCD34+CD38+CD123CD45RA+CD7+CD10+CD127), and mature NK (NKp46+CD56+CD3CD19CD33) cells. Data are from two different
Affymetrix analyses with three replicates for each population.
(C) Quantitative gene expression analysis of purified cell populations. Data show average expression levels of three experiments (three replicates per population
per experiment using 25 cells). #p% 0.001, below detection.
See also Figure S5.et al. (2014) might differ due to the fact that the CD16+CD56
phenotype used to identify NK cells is not entirely NK cell
specific.404 Immunity 43, 394–407, August 18, 2015 ª2015 Elsevier Inc.Here, we show that the LinCD34+CD38+CD123CD45RA+
CD7+CD10+CD127 population represents a NK cell lineage-
restricted progenitor in human umbilical cord blood, adult bone
AB
Figure 7. The Human NKP Is Downstream of LMPPs and CLP-like Cells in the Hematopoietic Hierarchy
500 CB purified LMPP (LinCD34+CD38CD90CD45RA+), CLP-like (LinCD34+CD38+CD123CD45RA+CD7+CD10+CD127+), and NKP (LinCD34+CD38+
CD123CD45RA+CD7+CD10+CD127) cells were cultured for 4 and 6 days onOP9 stroma and the phenotype of themaintained/generated cells was analyzed by
flow cytometry at day 0 (A) and at days 4 (D4) and 6 (D6) (B). The expression of CD122 was also evaluated on generated NKPs from the different progenitors. Data
are representative of three independent experiments using different batches of CB cells with six wells plated for each population for each experiment. See also
Figure S6.marrow, tonsil, and fetal tissues.Given the fact thatNKcells havea
central role in eliminating virus-infected and transformed cancer
cells, the identification of NKP will generate a greater depth of un-
derstanding of the origin of human NK cells and contribute to the
development of new protocols for NK cell-based therapy.EXPERIMENTAL PROCEDURES
Tissues
Human tissues were collected after informed consent and with the approval
from the ethical review boards at Lund University and Karolinska Institutet.
Donated human cord blood (CB) samples from Lund, Malmo¨, and Helsingborg
hospitals were diluted in heparin immediately after delivery and processed
within 24 hr. Human bonemarrow (BM) was obtained from healthy adult volun-
teers via aspiration of 60 ml from the hip bone and processed directly after.
Mononuclear cells from CB and BM were isolated on Lymphoprep (Axis-
Shield). Human tonsils were obtained from adults undergoing surgery at the
Karolinska University Hospital, Stockholm. Fetal tissues were donated fromelective abortions as well as purchased from Novogenix Laboratories. Human
fetal tissues were isolated as previously described (Medvinsky et al., 2008)
and procedures for preparation of single-cell suspensions are provided in
the Supplemental Experimental Procedures.
Antibodies, Flow Cytometry, and Cell Sorting
The single-cell suspensions were blocked by incubation with human Fc Re-
ceptor binding inhibitor (eBioscience) and then stained with specific human
monoclonal antibodies (mAb) listed in Table S1. Fluorescence minus one
(FMO) controls, with proper isotype controls, were used to determine the pos-
itive signals. 7-aminoactinomycin D (7-AAD, Sigma-Aldrich), TO-PRO-1 iodide
(1mM, Invitrogen), and DAPI (Invitrogen, 0.5 mg/ml) were used to exclude dead
cells from the analysis. Intracellular stainings were performed using Foxp3
transcription factor staining buffer kit (eBiosciences) as recommended by
the manufacturer and antibodies are listed in Table S2.
To identify theNKPcandidates, the followingAbsweremixed todefine the line-
age-negative (Lin) population: anti-CD3, CD4, CD11b, CD11c, CD14, CD15,
CD19, CD33, CD56, CD66b, and CD235a. For the fetal liver (FL) enriched
CD34+ population, only anti-CD3, CD14, CD15, CD19, CD33, CD56, CD66b,Immunity 43, 394–407, August 18, 2015 ª2015 Elsevier Inc. 405
and CD235a antibodies were used. Samples were analyzed on an LSR II (BD
Biosciences) and analysis was performed using FlowJo software (v.9.3;
TreeStar).
The CD34+ fractions were obtain from human CB, BM, and FL (from 6- to
16-week-old fetuses staged based on the developmental age) using CD34
positive selection (Miltenyi Biotec). After the staining with directly conjugated
antibodies, the LinCD34+CD38+CD123CD45RA+CD7+CD10+CD127 cells
were sorted. All sorts were performed on a BD FACSAria III (BD Biosciences)
and the average purity of sorted cells in all experiments was 93%.
OP9 and OP9-DL1 Cultures
OP9 and OP9-DL1 stroma cells were kindly provided by Dr. J.C. Zu´n˜iga-
Pflu¨cker, and cultures were carried out as previously described (Nozad Char-
oudeh et al., 2010; Schmitt and Zu´n˜iga-Pflu¨cker, 2002). Purified LinCD34+
CD38+CD123CD45RA+CD7+CD10+CD127 NKPs and LinCD34+ cells
(used as positive control) were co-cultured at 500, 10, or 1 cell per well on
OP9 and OP9DL1 stroma and generated progeny was analyzed by flow cy-
tometry. Details are provided in the Supplemental Experimental Procedures.
Terasaki Single-Cell Culture Assay
Single sorted LinCD34+CD38+CD123CD45RA+CD7+CD10+CD127 or
LinCD34+ cells from CB or BM were cultured for 14 days in the presence of
myeloid cytokines and scored for the size and morphology of generated
clones. See the Supplemental Experimental Procedures for details.
Transplantation Assay
Newborn NOD/SCIDgcnull (NSG) mice (Ito et al., 2002) were used as recipients
for human cell transplantation. The estimated delivery dates were determined
21 days after the vaginal plug was observed, as previously described (Tang
et al., 2012). Newborn recipient mice were irradiated with a 100 Gy 12 hr after
the delivery and were injected into the facial vein with 600 CB LinCD34+ or
CB LinCD34+CD38+CD123CD45RA+CD7+CD10+CD127 cells in 25 ml, be-
tween 2 and 6 hr after irradiation, as previously described (Park et al., 2008).
Mice were analyzed for the human cell engraftment at 4, 5, and 11 weeks
after transplantation. Details are provided in the Supplemental Experimental
Procedures.
Evaluation of NK Cell Activity
Functional activity of NK cells generated in vitro and after transplantation into
NOD/SCIDgcnull mice was evaluated using expression of CD107a (lysosomal
associated membrane protein 1; LAMP-1) (Bryceson et al., 2005) and secretion
of IFN-g and TNF-a. See the Supplemental Experimental Procedures for details.
Microarray Analysis
Global gene expression analysis was performed on the LinCD34+CD38+
CD123CD45RA+CD7+CD10+CD127 (NKP), LinCD34+CD38CD90
CD45RA+ (multipotent progenitors LMPP), LinCD34+CD38+CD123
CD45RA+CD7+CD10+CD127+ (common lymphoid progenitor [CLP]-like cell),
and CD3CD56+NKp46+ (mature NK cells) purified from CB (two experiments,
three replicates for each population). See the Supplemental Experimental Pro-
cedures for details.
Quantitative Gene Expression Analysis by Fluidigm
Multiplex real-time PCRanalysiswas performed using BioMark 48.48Dynamic
Array platform (Fluidigm) and TaqMan Gene Expression Assays (Life Technol-
ogies). For cDNA synthesis and preamplification of target Genes, CellsDirect
One-Step qRT-PCR kit (Invitrogen) was used. Twenty-five cells were sorted
directly into 96-well PCR plate containing 2.5 ml gene specific 0.23 TaqMan
gene expression assays (Applied Biosystems), 5 ml of CellsDirect 23 Reaction
mix (Invitrogen), 1.2 ml CellsDirect RT/Taq mix, 1.2 ml TE buffer, and 0.1 ml
SUPERase-In RNase Inhibitor (Ambion). Conditions for reverse transcription
and target geneamplificationwere: 15min at 50C;2minat 95C;and22cycles
of 95C for 15 s and60C for 4min. Preamplifiedproductswere diluted 1:5 in TE
buffer andanalyzedonDynamicArraywith the followingPCRcycling condition:
95C for 10 min and 40 cycles of 95C for 15 s and 60C for 60 s. Data were
analyzed via the DCt method: results were normalized to GAPDH expression
and expressed as mean expression level relative to GAPDH (±SEM). TaqMan
primers used for the analysis are listed in Table S3.406 Immunity 43, 394–407, August 18, 2015 ª2015 Elsevier Inc.Statistics
All results are expressed as mean (SD) or frequency of viable single cell (deter-
mined with Flow Jo software). The statistical significances between groups
were determined by the Mann-Whitney test.
ACCESSION NUMBERS
Data have been deposited into NCBI Gene Expression Omnibus portal under
the accession number GEO: GSE60448.
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Experimental Procedures and can be found with this article online at http://dx.
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